Serum markers of immune activation in women undergoing in-vitro fertilization and embryo transfer

Hum Reprod. 1996 Nov;11(11):2412-7. doi: 10.1093/oxfordjournals.humrep.a019126.

Abstract

We evaluated serum concentrations of two early and sensitive markers of immune activation, interleukin-2 receptor (sIL-2R) and intercellular adhesion molecule-1 (ICAM-1) in two age-matched groups of in-vitro fertilization (IVF)-embryo transfer women, group I (n = 26) without and group II (n = 40) with methylprednisolone (MPD) supplementation of the luteal phase, on the days of oocyte retrieval (sample A) and embryo transfer (B), and second (C) and 13th (D) days post-transfer and in 20 normally cycling women (controls) on the day of luteinizing hormone (LH) peak. No difference in the outcome of the IVF-embryo transfer was observed between groups I and II. In sample A, both immunomarker concentrations showed no significant difference between the two groups of IVF women, while they were significantly higher (P < 0.01) than values in controls. In cycles in which conception occurred, significantly higher immunomarker concentrations were observed in sample A of both groups I and II compared with those in unsuccessful cycles of the same group. A significant decrease of both sIL-2R and ICAM-1 was noticed in sample B only in group II (P < 0.0001 and P < 0.001 respectively; paired t-test) that continued further in the late luteal phase only in the case of conception, independently of MPD supplementation. These data suggest that (i) due to multiple ovulations, IVF-embryo transfer women show elevated concentrations of sIL-2R and ICAM-1 at oocyte retrieval; (ii) since, even at oocyte retrieval stage, high concentrations of immunomarkers are associated with IVF-embryo transfer success, sIL-2R and ICAM-1 could be used as early indicators for conception cycles; (iii) transient suppression of T cell activity by MPD supplementation following IVF-embryo transfer does not improve pregnancy rate.

MeSH terms

  • Embryo Transfer*
  • Female
  • Fertilization in Vitro*
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunity*
  • Immunosuppressive Agents
  • Intercellular Adhesion Molecule-1 / blood*
  • Interleukin-2 / blood*
  • Lymphocyte Activation
  • Methylprednisolone / therapeutic use
  • Pregnancy
  • T-Lymphocytes / immunology

Substances

  • Glucocorticoids
  • Immunosuppressive Agents
  • Interleukin-2
  • Intercellular Adhesion Molecule-1
  • Methylprednisolone